3 citations
,
January 2025 in “Scientific Reports” This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.
1 citations
,
January 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.
2 citations
,
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study observed that both SARS-CoV-2 and other acute respiratory infections are linked to a wide range of long-term symptoms, highlighting the need to investigate post-acute sequelae beyond COVID-19.
8 citations
,
June 2021 in “Annals of internal medicine” This article discusses the evaluation and management of long COVID, emphasizing the need for a multidisciplinary approach and coordinated efforts in both research and patient care but reports no new findings.
December 2021 in “Zenodo (CERN European Organization for Nuclear Research)” This case report describes a post-COVID syndrome patient who experienced symptoms like headache, joint pain, and swollen lymph nodes; treatment with Erbisol drugs reportedly alleviated symptoms and normalized immunological parameters.